Bristol Myers Squibb presents, publishes data from SCOUT-HCM trial of Camzyos ($58.54, 0.00)
Tarsus TP-03 0.25% approval in China for the treatment of Demodex Blepharitis triggers $15M milestone payment ($64.51, 0.00)
Powered by FactSet Research Systems Inc.